Abstract:1299 Since 1977, numerous studies have indicated the existence of a putative membrane-based estrogen receptor. However, the identity of this membrane-based estrogen receptor has not been established. Through an extensive homology search in Gene Bank, we recently identified and cloned a novel variant of ER-Α with a predicted molecular weight of 35.7 kDa. The transcript of this ER-Α variant is initiated from a previously unidentified promoter in the first intron of the original ER-Α gene. This ER-Α variant differs from the original ER-Α by lacking both transcriptional activation domains (AF-1 and AF-2) but retaining the dimerization, DNA-binding and partial ligand-binding domains. Its ligand-binding domain also possesses a unique 27 amino acid stretch that replaces the last 138 amino acids of the ER-Α. In transient transfection assays, this ER-Α variant exhibited no intrinsic transcriptional activity but strongly inhibited ligand-dependent and -independent transactivation activities mediated by the original ER-Α and ER-Β. Immunodetection and subcellular fractionation assays demonstrated that this ER-Α variant is expressed on the plasma membrane of mammary epithelial cells, and also in the cytoplasm and nucleus. In cells that express this ER-Α variant, 17Β-estradiol (E2) treatment activated a membrane-initiated effect of estrogen signaling by transiently activating the mitogen-activated protein kinase (MAPK) pathway that led to cell proliferation. Antiestrogens such as tamoxifen and ICI 182,780, however, strongly and persistently activated the MAPK pathway that then resulted in activation of the SAPK/JNK pathway. Immunohistochemistry analysis using a specific antibody aganst this ER-Α variant revealed that 26 of 38 cases (68%) breast cancer specimens examined express this ER-Αvariant on the plasma membrane and cytoplasm, and 12 out of 13 ER-negative breast caner specimens also express this ER-Α variant. Our findings demonstrate a physiologically important ER-Α variant that is involved in membrane-initiated estrogen signaling and suggest that aberrant expression of this ER-Α variant contributes to development of ER-positive and-negative human breast cancer.

Research Advance on a Novel Estrogen Receptor β

Research Progress of Estrogen ReceptorβIsoforms 1-5 in Cancers

Progress in study of selective ERβ ligands

Advances in Estrogen Receptor Β Coregulator

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

A novel variant of estrogen receptor-alpha is expressed in ER-negative breast cancer and mediates membrane-initiated estrogen signaling

Progress on Estrogen Receptor and Female Reproduction

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

The Role of Estrogen Receptor Beta in Breast Cancer.

[Molecular Mechanisms of Regulation of Estrogen Receptor a Expression Level in Breast Cancer].

Recent advance in the design of small molecular modulators of estrogen-related receptors.

Research Advances on Estrogen Receptor

Structural Insights into the Specificity of Ligand Binding and Coactivator Assembly by Estrogen-Related Receptor Β

The Research Advances in G-Protein-Coupled Estrogen Receptor

Estrogen Signals through ERβ in Breast Cancer; What We Have Learned since the Discovery of the Receptor

Quantitative Profiles of the Mrnas of ER-α and Its Novel Variant ER-α36 in Breast Cancers and Matched Normal Tissues

Identification, Cloning, and Expression of Human Estrogen Receptor-Α36, a Novel Variant of Human Estrogen Receptor-Α66

Distribution characteristics of terrestrial heat flow density in Jiyang depression of Shengli Oilfield, East China

Estrogen receptors in gastric cancer: Advances and perspectives

The Expression of Estrogen Receptor Α, Β in Different Breast Tissues and Its Relation with Breast Cancer

3d-Qsar And Docking Studies Of Estrogen Compounds Based On Estrogen Receptor Beta